Rafferty Asset Management
AVIR icon

Rafferty Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Rafferty Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,774
Closed -$114K – 1138
2022
Q1 		$114K Sell
15,774
-91,945
-85% -$624K ﹤0.01% 1167
2021
Q4 		$963K Buy
+107,719
New +$1.68M 0.01% 879

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Rafferty Asset Management's AVIR Position: Q2 2022 in Review

Rafferty Asset Management sold out of Atea Pharmaceuticals (AVIR) in Q2 2022, closing a stake of 15,774 shares — an estimated $114K sold.

Rafferty Asset Management first reported a position in AVIR in Q4 2021 and held it in 2 quarters. The position peaked at $963K in Q4 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q2 2022.

  • Rafferty Asset Management reported no remaining Atea Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 15,774 Atea Pharmaceuticals shares in Q2 2022, an estimated $114K.
  • Rafferty Asset Management first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Rafferty Asset Management's Atea Pharmaceuticals position peaked at $963K in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2022.

Based on Rafferty Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.